Pharmaceutical company Emcure set to dispense Sanofi's oral diabetes medication products
## Sanofi Partners with Emcure Pharmaceuticals to Expand Anti-Diabetic Products Reach in India
In a significant move to combat the rising prevalence of diabetes in India, Sanofi India and Emcure Pharmaceuticals have joined forces to distribute and promote Sanofi's oral anti-diabetic (OAD) products. The partnership, effective immediately, aims to expand the reach of Sanofi's trusted brands such as Amaryl (glimepiride) and Cetapin (metformin), utilizing Emcure's extensive distribution network across the country.
Under the terms of the agreement, Sanofi India will retain ownership of the brands and continue to manufacture them at its facilities in India and internationally. Emcure Pharmaceuticals, on the other hand, will exclusively distribute and promote these products, leveraging its strong network to engage healthcare professionals and increase accessibility for patients. There will be no transition of employees from Sanofi India to Emcure Pharmaceuticals as part of this agreement.
The partnership is expected to significantly increase access to Sanofi's OAD products for millions of Indians living with diabetes, particularly those with uncontrolled blood sugar levels. Emcure's extensive network will enhance the distribution capabilities of Sanofi's products, ensuring they reach more healthcare providers and patients across India. For Emcure, this agreement complements its existing diabetes portfolio, creating a comprehensive offering that supports better diabetes care nationwide.
With over 100 million Indians living with type 2 diabetes and more than 60% having uncontrolled blood sugar levels, this partnership is timely and critical for improving healthcare outcomes. Despite competition from generic brands, Sanofi's established brands are expected to benefit from Emcure's strong distribution capabilities and brand recognition among healthcare professionals.
This collaboration is a testament to Sanofi's commitment to improving diabetes care and accessibility in India. As the partnership progresses, it is expected to bring about positive changes in the management of diabetes in the country.
- This partnership between Sanofi India and Emcure Pharmaceuticals is a significant step towards expanding the reach of Sanofi's subscription-based health-and-wellness products, focusing particularly on its anti-diabetic products.
- Emcure Pharmaceuticals, in their effort to broaden their business, will exclusively distribute and promote Sanofi's finance-intensive oral anti-diabetic products, leveraging their strong network in the markets.
- The synergy between the two companies, Sanofi's established science-based products and Emcure's vast distribution network, promises to facilitate better access to diabetes care and management in India.
- With the support of Emcure's business strategies, Sanofi's health-and-wellness nutrition-centric products, including Amaryl and Cetapin, are expected to carve out a dominant space in the Indian markets.
